I am a
Home I AM A Search Login

Papers of the Week

Papers: 23 Jul 2022 - 29 Jul 2022

2022 Jul 23




Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.


Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong C-HH, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U
Lancet. 2022 Jul 23; 400(10348):273-282.
PMID: 35871814.


Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-to-severe atopic dermatitis, a common immunoinflammatory skin disease. This study assessed the efficacy and safety of abrocitinib versus dupilumab.